Entera Bio (ENTX) investor relations material

Company overview and business model

• Focuses on developing first-in-class oral tablet formats of peptides or protein replacement therapies for chronic conditions, leveraging the proprietary N-Tab® platform to enable oral delivery of large hydrophilic peptides and proteins.

• Pipeline includes oral peptide programs targeting PTH (1-34), GLP-1/Glucagon, and GLP-2 for osteoporosis, hypoparathyroidism, obesity, metabolic, and gastrointestinal disorders.

• Collaborates with OPKO Biologics on multiple programs, sharing development costs and ownership for certain assets.

Financial performance and metrics

• Raised approximately $10 million in a private placement on April 2, 2026, selling 7,827,789 units at $1.2775 per unit.

• If all Ordinary Share Warrants are exercised for cash, could receive up to $14.5 million in additional proceeds.

• Financial statements include a going concern explanatory paragraph, indicating ongoing funding needs.

Use of proceeds and capital allocation

• Net proceeds from warrant exercises, if any, will support the initiation of a phase 3 registrational study of EB613 in postmenopausal women with osteoporosis and for general working capital and corporate purposes.